Essential Differences Between Breast Biopsy And Imaging Screening

https://www.mayoclinic.org/tests-procedures/breast-biopsy/about/pac-20384812

Pain Points In clinical breast disease screening, many medical institutions and patients confuse imaging screening and biopsy diagnosis, resulting in unreasonable diagnostic schemes and missed treatment opportunities. Mammography, ultrasound and MRI can only observe the morphological changes of breast tissue, but cannot identify the internal cellular pathological properties of lesions, leading to frequent false-positive and false-negative results. Many suspicious lesions judged as abnormal by imaging cannot be confirmed for benign and malignant properties, resulting in long-term follow-up observation and psychological anxiety of patients. Blind treatment based on imaging empirical judgment easily causes excessive resection of benign lesions and missed intervention of early malignant lesions. The lack of clear differentiation between screening and definitive diagnosis restricts the standardized and accurate diagnosis of breast diseases.

Working Principle The essential difference between breast biopsy and imaging screening lies in the diagnostic logic and technical dimension. Imaging screening belongs to morphological imaging diagnosis, which judges lesion risk through tissue density, shape and boundary changes, and is only used for preliminary screening of suspicious lesions. Breast biopsy belongs to cellular pathological definitive diagnosis, which obtains lesion tissue samples through professional biopsy needles, observes cellular structure changes under a microscope, and accurately judges lesion benignity, malignancy and pathological typing. Imaging screening is the preliminary screening link to find abnormal lesions, while breast biopsy is the final confirmation link to verify lesion properties. Biopsy makes up for the fatal defect that imaging cannot identify cellular pathology, forming a complete diagnostic closed-loop of "imaging screening + biopsy confirmation".

Equipment Classification Breast biopsy equipment supporting definitive diagnosis is divided into three graded types, forming a complete diagnostic equipment system different from imaging equipment. First, disposable polymer biopsy needles, matching routine imaging-positive lesion screening and confirmation, suitable for large-scale primary screening definitive diagnosis, low cost and safe. Second, stainless steel reusable biopsy needles, matching routine imaging suspicious lesion reexamination and pathological confirmation, stable performance and high cost performance. Third, titanium alloy high-precision biopsy needles, matching unclear tiny lesions and microcalcification lesions found by high-precision imaging, realizing ultra-precise tissue sampling and accurate definitive diagnosis. All biopsy needle specifications are designed for pathological sampling needs, completely different from imaging scanning equipment.

Practical Operation Guide Formulate standardized diagnostic matching procedures based on the essential differences between screening and biopsy. First, complete imaging screening first: use ultrasound or mammography to screen breast tissue, mark suspicious lumps, microcalcifications and non-palpable lesions. Second, judge biopsy indication: implement biopsy definitive diagnosis for all imaging-positive suspicious lesions with unclear properties. Third, select targeted biopsy needles: use high-gauge thin needles for imaging-found micro-lesions, and medium and low-gauge needles for large solid lesions. Fourth, complete pathological detection after sampling: realize qualitative diagnosis and molecular analysis, and take biopsy pathological results as the only standard for final diagnosis, abandoning simple imaging empirical judgment to ensure diagnostic accuracy.

Practical Experience Clinical big data verification shows that more than 30% of imaging-suspected malignant breast lesions are finally confirmed as benign by biopsy, avoiding unnecessary surgical trauma and medical consumption. At the same time, nearly 15% of early malignant lesions with atypical imaging morphology are accurately detected by biopsy, solving the problem of missed diagnosis of pure imaging screening. The two technologies form an effective complementary mechanism: imaging efficiently screens abnormal areas in a large range, and biopsy accurately confirms pathological properties. Standardized collaborative application greatly improves the efficiency and accuracy of breast disease diagnosis, realizing precise screening and precise treatment of breast diseases.

Summary and Sublimation Breast biopsy is the only definitive diagnostic technology that cannot be replaced by imaging screening, representing the deepest dimension of breast disease diagnosis from morphological observation to cellular pathological confirmation. The essential difference in technical principles determines the hierarchical application logic of "screening first and confirmation later". Biopsy technology completely makes up for the limitations of imaging screening, eliminates the uncertainty of empirical diagnosis, and provides absolutely accurate pathological basis for clinical diagnosis and treatment. It is an indispensable core link in the standardized diagnostic system of modern breast diseases.

Future Suggestions Future clinical diagnosis will further standardize the collaborative application of screening and biopsy. First, formulate unified indication standards for biopsy intervention after imaging screening to avoid excessive biopsy and missed diagnosis. Second, promote the intelligent matching of imaging lesion characteristics and biopsy needle specifications to improve diagnostic efficiency. Third, strengthen public science popularization to distinguish screening and definitive diagnosis, reduce patient misjudgment and medical anxiety. Fourth, build an integrated diagnosis system of imaging intelligent screening and biopsy precise confirmation to realize full-process intelligent diagnosis of breast diseases.